Impact of hematopoietic stem cell transplantation in patients with relapsed or refractory mantle cell lymphoma

Satoshi Yamasaki, Dai Chihara, Sung Won Kim, Koji Izutsu, Kouji Iwato, Takahiro Fukuda, Naoyuki Uchida, Itsuto Amano, Hideyuki Nakazawa, Junya Kuroda, Hisako Hashimoto, Tatsuo Ichinohe, Yoshinobu Kanda, Yoshiko Atsuta, Junji Suzumiya, Ritsuro Suzuki

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Abstract

Rituximab has been shown to improve outcomes in patients with B-cell lymphoma. However, patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) still have a poor prognosis, and the choice between high-dose therapy with autologous hematopoietic cell transplantation (HCT) and allogeneic HCT remains controversial in these patients. We retrospectively analyzed the risk factors for outcomes in 162 R/R MCL patients who received autologous (n = 111) or allogeneic (n = 51) HCT between 2004 and 2014. The median overall survival (OS) rates were 48 and 65 months in the autologous and allogeneic HCT groups, respectively (P = 0.20). Significant risk factors for overall survival in R/R MCL patients after autologous HCT were > 60 years of age at HCT (P = 0.017), higher score of HCT-specific comorbidity index at HCT (P = 0.033), and receiving MCEC (ranimustine + carboplatin + etoposide + cyclophosphamide) regimen (P = 0.017), while higher performance status at HCT (P = 0.011) and longer interval from diagnosis to HCT (P = 0.0054) were risk factors after allogeneic HCT. Strategies that carefully select R/R MCL patients for autologous HCT may allow the identification of individuals suitable for allogeneic HCT.

Original languageEnglish
Pages (from-to)1445-1452
Number of pages8
JournalAnnals of Hematology
Volume97
Issue number8
DOIs
Publication statusPublished - Aug 1 2018
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Hematology

Fingerprint Dive into the research topics of 'Impact of hematopoietic stem cell transplantation in patients with relapsed or refractory mantle cell lymphoma'. Together they form a unique fingerprint.

Cite this